Efficacy and Safety of Semaglutide Injection (HD1916) in Patients With Type 2 Diabetes Mellitus
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 506 participants.
Also called NCT06161844
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 506 participants
- Registry
-
NCT06161844
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT06161844. Randomized; no masking; primary purpose treatment. Start 2024-02-23 (actual); primary completion 2025-05-14 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Efficacy and Safety of Semaglutide Injection (HD1916) in Patients With Type 2 Diabetes Mellitus
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- semaglutide injection (HD1916)
- Intervention (Drug)
- Ozempic®
- Lead sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Record details
- Record id
cardio:ct-nct06161844- Content hash
b2fbcd8a5896459fee579997a533ae5135f7ffded37c4537d6498326f50bdaf5